Home > > > Report Detail

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's ‘Adrenoleukodystrophy (ALD)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Adrenoleukodystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2016-2028

Adrenoleukodystrophy Epidemiology

The Adrenoleukodystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Adrenoleukodystrophy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adrenoleukodystrophy Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, diagnosed prevalence of ALD by clinical manifestations (cerebral ALD, Adrenomyleoneuropathy and Addison's disease), diagnosed prevalence of CALD by segmentation (childhood, adolescent, adult ALD)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, total prevalent cases of Adrenoleukodystrophy in 7 major markets are found out to be 26,866 in 2016.

Report Scope

- The report covers detailed overview of Adrenoleukodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- The report provides the insight about the historical and forecasted patient pool of Adrenoleukodystrophy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Report assesses the disease risk and burden and highlights the unmet needs of the disease

- The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

- The report provides the segmentation of the disease epidemiology by Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM

Key strengths

- 10 Year Forecast of Adrenoleukodystrophy epidemiology

- 7MM Coverage

- Total Prevalent Cases of Adrenoleukodystrophy

- Prevalent Cases according to segmentation: Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM

- Diagnosed cases of Adrenoleukodystrophy

Key assessments

- Patient Segmentation

- Disease Risk & Burden

- Risk of disease by the segmentation

- Factors driving growth in a specific patient population

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2028

Table of Contents

1. Key Insights
2. Disease Background and Overview: Adrenoleukodystrophy (ALD)
2.1. Introduction
2.2. Clinical aspects of ALD
2.3. Disease Causes
2.4. Inheritance pattern of ALD
2.5. ALD-Symptoms
2.6. Pathogenesis
2.7. ALD Diagnosis
2.8. X-ALD Newborn Screening
2.9. Tools for evaluating Cerebral X-ALD
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Disease Definition
3.3. Population and Forecast Parameters
4. 7MM Prevalent Population of Adrenoleukodystophy (ALD)
5. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD)
5.1. United States
5.1.1. Prevalent Population of Adrenoleukodystrophy in United States
5.1.2. Diagnosed Prevalence of ALD by Clinical Manifestation in United States
5.1.3. Diagnosed Prevalence of CALD by Segmentation in United States
5.2. Germany
5.2.1. Prevalent Population of Adrenoleukodystrophy in Germany
5.2.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany
5.2.3. Diagnosed Prevalence of CALD by Segmentation in Germany
5.3. France
5.3.1. Prevalent Population of Adrenoleukodystrophy in France
5.3.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the France
5.3.3. Diagnosed Prevalence of CALD by Segmentation in France
5.4. Italy
5.4.1. Prevalent Population of Adrenoleukodystrophy in Italy
5.4.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy
5.4.3. Diagnosed Prevalence of CALD by Segmentation in Italy
5.5. Spain
5.5.1. Prevalent Population of Adrenoleukodystrophy in Spain
5.5.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain
5.5.3. Diagnosed Prevalence of CALD by Segmentation in Spain
5.6. United Kingdom
5.6.1. Prevalent Population of Adrenoleukodystrophy in United Kingdom
5.6.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the United Kingdom
5.6.3. Diagnosed Prevalence of CALD by Segmentation in United Kingdom
5.7. Japan
5.7.1. Prevalent Population of Adrenoleukodystrophy in Japan
5.7.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan
5.7.3. Diagnosed Prevalence of CALD by Segmentation in Japan
6. Appendix
7. Report Methodology
7.1. Sources used
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight

List of Tables

Table 1: X-ALD Phenotypes in Males
Table 2: Phenotype in Female X-ALD carriers
Table 3: The X-ALD Phenotypes
Table 4: MRI Severity Scale
Table 5: MRI Severity Rating (Loes Score)
Table 6: Neurological Function Score (NFS Score)
Table 7: X-linked Adrenoleukodystrophy- Disability Rating Scale (ALD-DRS)
Table 8: Prevalent Population of Adrenoleukodystophy in the 7MM (2016-2028)
Table 9: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028)
Table 10: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028)
Table 11: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028)
Table 12: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028)
Table 13: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028)
Table 14: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028)
Table 15: Prevalent Population of Adrenoleukodystrophy in France (2016-2028)
Table 16: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028)
Table 17: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028)
Table 18: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028)
Table 19: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028)
Table 20: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028)
Table 21: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028)
Table 22: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028)
Table 23: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028)
Table 24: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028)
Table 25: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028)
Table 26: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028)
Table 27: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028)
Table 28: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028)
Table 29: Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028)

List of Figures

Figure 1: Evolution of Phenotypes in X-ALD
Figure 2: Clinical Spectrum of X-ALD
Figure 3: Inheritance spectrum of X-ALD
Figure 4: Pathogenesis of VLCFA
Figure 5: Principles of ALD 3-tier screening
Figure 6: Diagnostic algorithm for diagnosis of adrenoleukodystrophy
Figure 7: Prevalent Population of X-Adrenoleukodystophy in the 7MM (2016-2028)
Figure 8: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028)
Figure 9: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028)
Figure 10: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028)
Figure 11: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028)
Figure 12: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028)
Figure 13: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028)
Figure 14: Prevalent Population of Adrenoleukodystrophy in France (2016-2028)
Figure 15: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028)
Figure 16: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028)
Figure 17: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028)
Figure 18: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028)
Figure 19: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028)
Figure 20: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028)
Figure 21: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028)
Figure 22: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028)
Figure 23: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028)
Figure 24: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028)
Figure 25: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028)
Figure 26: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028)
Figure 27: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028)
Figure 28 Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028)
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs